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integrity of the hypothalamic pituitary axis is compromised
during severe infection. The observed blunted response to
corticotropin was interpreted as impaired secretory reserve
of the adrenal glands and was denoted as relative adrenocortical
insufficiency (RAI). In septic shock, a blunted response to
corticotropin prognosticates poor outcome, but resolves after
complete recovery (1, 2). Combined with a decreased cellular
sensitivity to steroids, the blunted response to corticotropin was
proposed to define critical illness-related corticosteroid insuf-
ficiency. The international ACCM/SCCM task force used this
term to highlight that any critical illness associated with
an overwhelming systemic inflammation may compromise
adrenocortical function, though the majority of studies related
to RAI focused on patients in septic shock.
The concept of RAI in critical illness is still a matter of
debate. In a milestone study published a few years ago, Boonen
et al. clearly demonstrated that cortisol clearance is reduced to
40% in critically ill patients with hyperlactatemia (2.58 mmol/
L) and 34 points APACHE II score. The lower clearance was
deemed responsible for the elevated cortisol levels observed in
critical illness (3). Interestingly, the lower cortisol clearance
was also associated with less cortisol response to corticotropin
(3). Although high cortisol levels appear to argue against a
syndrome of corticosteroid insufficiency, the combination of
high cortisol levels and a blunted response to corticotropin
showed the poorest prognosis in septic shock (1).
Despite these new insights into cortisol metabolism during
critical illness, the prognostic value of a short corticotropin test
has been demonstrated in many studies, also in shock states not
caused by sepsis. In this issue of Shock, Bagate et al. (4)
demonstrate that a blunted response to corticotropin was an
independent predictor for hospital and long-term mortality in
patients with cardiogenic shock. By combining cortisol levels
at baseline with the increase of cortisol after corticotropin, the
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498groups. Based on the data of 92 patients with cardiogenic
shock, adrenal response to corticotropin was considered to
be inappropriate with an increase in cortisol 473 nmol/L.
In presence of high cortisol levels at baseline (>798 nmol/L)
this group of patients had the poorest long-term prognosis.
Cardiogenic shock shares immune mechanisms with septic
shock. Low-flow state and systemic inflammation causes endo-
thelial damage and organ dysfunctions very similar to sepsis.
Inflammatory mediators, oxidative stress, and overproduction of
nitric oxide may be responsible for vasodilation and low systemic
vascular resistance observed in many patients with confirmed
cardiogenic shock complicating acute myocardial infarction.
Excessive oxidative stress as present in shock has been identified
to suppress steroidogenesis in adrenal glands (5). This may
explain why the adrenal responsiveness is altered in the majority
of patients with severe cardiogenic shock.
The key question to answer is whether to treat or not to treat
RAI in cardiogenic shock. In septic shock, two large-scale
randomized trials gave conflicting results: Short corticotropin
test identified patients who showed a benefit to steroid treat-
ment in one study, but not in the other study. Studies revealed
interassay variations in samples of patients with septic shock
thus complicating the diagnosis of RAI (6). Other confounding
factors like the use of etomidate, deep sedation, or a preceding
long-term treatment with corticosteroids may further compli-
cate the correct diagnosis of RAI in the individual patient. For
these reasons, the surviving sepsis campaign does not recom-
mend corticotropin testing in septic shock to indicate steroid
treatment.
In a gene knockout model simulating RAI (i.e., a murine
model that shows normal corticosterone level under physio-
logic conditions, but a lack of inducible corticosterone pro-
duction in response to corticotropin or septic stress) treatment
with corticosteroid protected against sepsis after cecal ligation
and puncture. This study also showed that steroids may harm
wild-type mice with unaltered adrenocortical responsiveness
(7). A harm of steroid therapy in human septic shock has not
(yet) been demonstrated. However, a small pilot study in
patients with cardiogenic shock found that corticosteroids
therapy was an independent risk factor of death in a logistic
regression model (8).ized reproduction of this article is prohibited.
SHOCK OCTOBER 2017 EDITORIAL COMMENT 499So, what shall we do? First, we should not harm patients. In
other words, steroid treatment of patients with cardiogenic
shock should only be used in controlled clinical trials. Second,
we need more information on compromised adrenocortical
function in shock states. The use of corticotropin test is a good
first step. The goal is to identify patients who should, and—
more important—patients who should not be treated with
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